Effect of leukotriene modifier drugs on the safety of oral aspirin challenges

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 5, 2006, Pages 688-693

  White, Andrew ^a   Ludington, Elizabeth ^c   Mehra, Purvi ^b   Stevenson, Donald D ^b   Simon, Ronald A ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b SCRIPPS CLINIC   (United States)

^c Building 624 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LEUKOTRIENE; LONG ACTING DRUG; MONTELUKAST; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CHEST TIGHTNESS; CONJUNCTIVA; CORTICOSTEROID THERAPY; DESENSITIZATION; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FLUSHING; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPOTENSION; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD; NOSE CONGESTION; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT SELECTION; PERIORBITAL EDEMA; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; RESPIRATORY TRACT DISEASE; RHINORRHEA; SIDE EFFECT; SNEEZING; SYSTEMIC THERAPY; URTICARIA; WHEEZING;

EID: 33845219390     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61101-5     Document Type: Article

References (19)

1. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328:434.
2. Fahrenholz JM. Natural history and clinical features of AERD. Clin Rev Allergy Immunol. 2003;24:113-124.
3. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111:180-186.
4. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24:159-168.
5. Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kielbasa B. Aspirin intolerance and the cyclooxygenase-leuktotriene pathways. Curr Opin Pulm Med. 2003;10:51-56.
6. Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax. 2000;55:S45-S47.
7. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med. 2000;161:391-398.
8. Dafferen PJ, Muilenberg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol. 1999;104:559-564.
9. Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J. 1989;2:127-129.
10. Ghannam RD, Schreier L, Vanselow NA. Fatal bronchial asthma: an analysis of terminal treatment in twenty cases. Ann Allergy. 1968;26:194-205.
11. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111:913-921.
12. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;95:330-335.
13. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002;32:1491-1496.
14. Stevenson DD, Simon RA, Zuraw BL. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Adkinson NF, Yuninger JW, Busse WW et al, eds. Middleton's Allergy: Principles and Practice. 6th ed. Philadelphia, PA: Mosby; 2003:1695-1710.
15. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000;85:477-482.
16. Micheletto C, Tognella S, Visconti M, et al. Montelukast 10mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy. 2004;59:289-294.
17. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-30536.
18. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins and histamine into the nasal secretions of aspirin-sensitive asthmatics during reactions to aspirin. Am Rev Respir Dis. 1988;137:847-854.
19. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol. 1994;94:1046-1056.